TABLE 3.
Clinical recommendations for the use of anticoagulants in special populations infected with COVID‐19.
Special population | Recommendations and dosage | Study or guideline (year) |
---|---|---|
Obesity (BMI ≥30 kg/m2) or morbid obesity (BMI ≥40 kg/m2) | When hospitalized, intermediate‐dose or weight‐adjusted LMWH as a thromboprophylaxis regimen should be considered. | Spyropoulos et al. (2020) 92 |
Renal impairment | When CrCl <30 mL/min or acute kidney injury occurred, 5000 units of UFH subcutaneously two or three times a day or low‐dose LMWH should be considered. | OBE et al. (2020) 93 |
Pregnant women |
Antepartum evaluation
Postpartum evaluation
|
RCOG (2022) 94 |
Antepartum evaluation
Postpartum evaluation
|
NIH (2022) 95 | |
Pediatrics | When hospitalized with significantly increased D‐dimer or superimposed clinical risk factors for hospital‐related VTE, initiation of low‐dose LMWH subcutaneously twice a day should be considered. | Goldenberg et al. (2020) 96 |
Abbreviations: BMI, body mass index; COVID‐19, coronavirus disease 2019; CPAP, continuous positive airway pressure; CrCl, creatinine clearance; LMWH, low‐molecular‐weight heparin; NIH, National Institute of Health; RCOG, Royal College of Obstetricians and Gynecologists; UFH, unfractionated heparin; VTE, venous thromboembolism.